Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193009 | 1.00 | ATM (0.60) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL203326 | 1.00 | ATM (0.60) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL28109187 | 0.87 | ATM (0.53) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL28109189 | 0.87 | ATM (0.53) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL853344 | 0.87 | CYP2C19 (0.56) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3265138 | 0.87 | CYP2C19 (0.56) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3265315 | 0.87 | CYP2C19 (0.56) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL23346140 | 0.85 | CYP2C9 (0.51) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL16938797 | 0.85 | CYP2D6 (0.51) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL8750061 | 0.85 | CYP2C9 (0.51) | ATMCYP2D6CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981879-B | Method for preparing NS5A inhibitor-wipatasvir | 南通常佑药业科技有限公司 | 2021-03-05 | — | — | CN | claimed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | claimed |
| CN-110981879-A | Method for preparing NS5A inhibitor-wipatasvir | 南通常佑药业科技有限公司 | 2020-04-10 | — | — | CN | claimed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | claimed |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-07 | — | — | US | claimed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | claimed |
| EP-3686185-B1 | FLUORENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING HCV-RELATED DISEASE | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2023-12-13 | — | — | EP | disclosed |
| US-11261175-B2 | Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-03-01 | — | — | US | disclosed |
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210139493-A1 | PREPARATION OF VELPATASVIR AND DERIVATIVE THEREOF | SHANGHAI FOREFRONT PHARMACEUTICAL CO LTD (CN) | 2021-05-13 | — | — | US | disclosed |
| CN-110981879-B | Method for preparing NS5A inhibitor-wipatasvir | 南通常佑药业科技有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0738269-B1 | PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | URIACH & CIA SA J (ES) | 2000-04-26 | — | — | EP | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| US-5705504-A | PLATELET ACTIVATING FACTOR | J. URIACH & CIA, S.A. (ES) | 1998-01-06 | — | — | US | disclosed |
| EP-0738269-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996014317-A1 | NOVEL PIPERIDINE DERIVATIVES WITH PAF ANTAGONIST ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | ATM 2741/4885CYP2D6 226/4885CYP2C9 456/4885 |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ATM 2987/4885CYP2D6 3061/4885CYP2C9 3743/4885 |
| US-11261175-B2 | Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease | SLC10A1, SLC39A11, FAR1 | ATM 4624/4885CYP2D6 2295/4885CYP2C9 1707/4885 |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ATM 2987/4885CYP2D6 3061/4885CYP2C9 3743/4885 |
| US-20210139493-A1 | PREPARATION OF VELPATASVIR AND DERIVATIVE THEREOF | SAMHD1, TYMP, PNP | ATM 1554/4885CYP2D6 166/4885CYP2C9 137/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | ATM 2987/4885CYP2D6 3061/4885CYP2C9 3743/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ATM 2987/4885CYP2D6 3061/4885CYP2C9 3743/4885 |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | ATM 2987/4885CYP2D6 3061/4885CYP2C9 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.